Archiwum hase³
Fracture of orbital floor | Dupuytren's fracture | Galeazzie's fracture | Fracture of head of ulna | Fracture of head of femur | Fracture of distal end of humerus | Fracture of greater tuberosity of humeru | Fracture of thumb | Fracture of lateral malleolus | Fracture of medial malleolus | Fracture of bone | Fracture of ilium | Fracture of parietal bone | atrophy of lymphoid tissue | mean arterial pressure {MAP} | bioavailability profile | blastocyst | bone tissue density | bone tissue metabolism | bridging vein | caffeine pharmacokinetics . | calcification focus | calcium metabolism | calcium mobilisation | capillary permeability | carcinogenicity | cardiovascular collapse | cerebripetal | chloramphenicol | cholestyramine | chromosomal damage | Marketing Authorisation number (s) | Marketing Authorisation Holder | Neoplasm of corpus callosum | post-traumatic stress disorder {PTSD} | random amplified polymorphic DNA {RAPD} | elevation of transaminase level | elevation of serum ferritin | cleft palate | clomipramine | coagulation factor | conjugation | conjunctival sac | consequent reperfusion | coronary perfusion | coronary circulation | coronary flow | covalent bond | croscarmellose sodium | crystalline powder | cyclooxygenase activity | delirium symptoms | demethylation | diclofenac | dimethylxanthine | dopaminergic system | desipramine | Abscess of prostate | Alpha-fetoprotein (AFP) Blood Test | surfactant | multiple pregnancy | gestational age | deplete | subsidence | Fowler`s position | non-ulcer dyspepsia | forebrain | drug hepatotoxicity | ear buzzing | electrocardiographic test | electrostimulation | endocrine system | enzymatic activity | enzyme activity | ergotamine | ethynylestradiol | First line treatment | first line therapy | excessive perspiration | hair loss | expiratory wheezing | extrahepatic tissue | fentanyle | first-pass effect | flight of ideas | foetus | freely soluble | fungal suspension | gamma-carboxylation | gastric emptying rate | gastric mucosa | gastrointestinal mucosa | gastrointestinal peristalsis | peristalsis | gastrointestinal ulceration | genotoxic activity | glaucoma attack | glucuronidation | glutathione system | guanetidine | haemodynamic parameter | hand tremor | heart rhythm disorders | hepatic metabolism | heterogeneity of the results | Hill coefficient | glioneuroma | retrograde ejaculation | Bayesian Analysis | corpectomy | nerve root | nerve root retractor | chisel | facilitation | homeostasis | hydroxyl radicals | hyperglycemic effect | hypertension crisis | hypertensive crisis | hypophysial adenoma | impaired nasal patency | inactivation | creatinine kinase | increased leukocytosis | infectious factor | inflammation | influenza virus strain | inhibitor | inotropic effects | interindividual variability | intestinal wall | intracerebral haemorrhage | intramural nerve plexus | intraspinal anaesthesia | intravenous | isobolographic analysis | isoenzyme | isotope-labelled | catecholamine | ketoprofen | kinine | liver enlargement | liver enzymatic system | liver lobule | lumbar section | lumen of the gastrointestinal tract | lymphoid gland | lymphoid tissues | motor activity | malnutrinion | mammary gland | pharmacodynamic activity | meloxicam | metamisol | methylene chloride | methylxanthine | metoclopramide | metoxamine | mexiletine | microglia | micronuclear test | monoaminooxidase {MAO} | morula | myocardium | myocardium contractility | N-acetyl-p-benzo-quinone imine | naphazoline | naproxen | nasal mucosa | nerve endings | nimesulid | non-selective antagonist | non-steroid anti-inflammatory drug | normalisation of biochemical parameters | omeprazole | Stable coronary artery disease | presenile dementia Alzheimer's type | insertion | operating theater | health visitor | bottom | lubricate | eschar | arborization | ovulation | orchiatrophy | ossification disorders | oxidative desamination | oxygen consumption | oxymetazoline | pain receptor | Failed medical abortion | Postencephalitic parkinsonism | proline | perioperative risk | paracetamol | paracetamol clearance | paraxanthine | parecoxib | parenteral feeding |
Poprzednia 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 Nastêpna
